|
Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC). |
|
|
Consulting or Advisory Role - Seagen |
Research Funding - Seagen |
|
|
Employment - Abbvie (I); Seagen |
Stock and Other Ownership Interests - Abbvie (I); Seagen |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - Johnson & Johnson |
|
|
Employment - Genentech/Roche; Seagen |
Stock and Other Ownership Interests - Genentech/Roche; Seagen |
Travel, Accommodations, Expenses - Genentech/Roche; Seagen |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Seagen |
Consulting or Advisory Role - Preveta |
|
|
Employment - Flatiron Health |
Consulting or Advisory Role - AstraZeneca; Bayer; Biovica; Bristol-Myers Squibb; Genentech (Inst); GRAIL; Merck; Pfizer; Seagen |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Microsoft (Inst) |
Travel, Accommodations, Expenses - Bayer; Bayer Schering Pharma; Bristol-Myers Squibb; Flatiron Health; GRAIL |
|
|
Research Funding - Seagen |
|
|
Consulting or Advisory Role - Curta Consulting |